Business
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in
About this update from Cg Oncology, Inc.
[{"type":"text","content":"- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -\nIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association (AUA) Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024. CG Oncology is exhibiting at the AUA meeting at booth #100. “We are excited to share encouraging 12-month Phase 3 monotherapy results from the BOND-003 study at AUA 2024,” said Ambaw Bellete, President and Chief Operating Officer, CG Oncology. “Our presence reinforces our commitment to improving outcomes for patients diagnosed with bladder cancer across the disease spectrum.” Details of the oral presentations are as follows: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in SituAbstract Number: 24-11358Session: Paradigm-shifting, Practice-changing Clinical Trials in UrologyPresenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZPresentation Date & Time: May 3, 2024, 10:23-10:31am Central Daylight TimeLocation: Henry B. González Convention Center, Stars at Night Ballroom PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder TumorSession: Clinical Trials in Progress, Bladder CancerPresenter: Robert Svatek, M.D., Urologic Oncologist at University of Texas Health Science Center, San Antonio, TXPresentation Date & Time: May 5, 2024, 10:24-11:32am Central Daylight TimeLocation: Henry B. González Convention Center, Learning Lab BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladde...